Mustang Bio Past Earnings Performance
Past criteria checks 0/6
Mustang Bio's earnings have been declining at an average annual rate of -19%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 21.8% per year.
Key information
-19.0%
Earnings growth rate
13.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -21.8% |
| Return on equity | -249.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Mustang Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -74 | 11 | 62 |
| 31 Dec 22 | 0 | -78 | 12 | 64 |
| 30 Sep 22 | 0 | -78 | 12 | 64 |
| 30 Jun 22 | 0 | -76 | 11 | 64 |
| 31 Mar 22 | 0 | -71 | 11 | 60 |
| 31 Dec 21 | 0 | -66 | 11 | 56 |
| 30 Sep 21 | 0 | -67 | 11 | 57 |
| 30 Jun 21 | 0 | -63 | 11 | 50 |
| 31 Mar 21 | 0 | -63 | 11 | 49 |
| 31 Dec 20 | 0 | -60 | 10 | 47 |
| 30 Sep 20 | 0 | -56 | 9 | 43 |
| 30 Jun 20 | 0 | -53 | 9 | 43 |
| 31 Mar 20 | 0 | -49 | 9 | 38 |
| 31 Dec 19 | 0 | -46 | 10 | 36 |
| 30 Sep 19 | 0 | -42 | 10 | 32 |
| 30 Jun 19 | 0 | -39 | 9 | 30 |
| 31 Mar 19 | 0 | -34 | 8 | 27 |
| 31 Dec 18 | 0 | -31 | 7 | 24 |
| 30 Sep 18 | 0 | -34 | 6 | 27 |
| 30 Jun 18 | 0 | -34 | 9 | 23 |
| 31 Mar 18 | 0 | -34 | 9 | 23 |
| 31 Dec 17 | 0 | -31 | 9 | 20 |
| 30 Sep 17 | 0 | -24 | 9 | 15 |
| 30 Jun 17 | 0 | -19 | 6 | 13 |
| 31 Mar 17 | 0 | -15 | 5 | 9 |
| 31 Dec 16 | 0 | -13 | 3 | 9 |
| 30 Sep 16 | 0 | -6 | 2 | 3 |
| 30 Jun 16 | 0 | -5 | 1 | 3 |
| 31 Mar 16 | 0 | -4 | 1 | 3 |
Quality Earnings: 2W60 is currently unprofitable.
Growing Profit Margin: 2W60 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2W60 is unprofitable, and losses have increased over the past 5 years at a rate of 19% per year.
Accelerating Growth: Unable to compare 2W60's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2W60 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 2W60 has a negative Return on Equity (-249.62%), as it is currently unprofitable.